Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.53
PACB's Cash to Debt is ranked lower than
61% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. PACB: 5.53 )
Ranked among companies with meaningful Cash to Debt only.
PACB' s Cash to Debt Range Over the Past 10 Years
Min: 3.98  Med: 22.27 Max: No Debt
Current: 5.53
Equity to Asset 0.66
PACB's Equity to Asset is ranked lower than
52% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PACB: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
PACB' s Equity to Asset Range Over the Past 10 Years
Min: -2.1  Med: 0.66 Max: 0.92
Current: 0.66
-2.1
0.92
F-Score: 5
Z-Score: -2.05
M-Score: -0.90
WACC vs ROIC
23.24%
-424.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -53.75
PACB's Operating margin (%) is ranked higher than
56% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. PACB: -53.75 )
Ranked among companies with meaningful Operating margin (%) only.
PACB' s Operating margin (%) Range Over the Past 10 Years
Min: -65237.04  Med: -343.6 Max: -31.4
Current: -53.75
-65237.04
-31.4
Net-margin (%) -56.04
PACB's Net-margin (%) is ranked higher than
54% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. PACB: -56.04 )
Ranked among companies with meaningful Net-margin (%) only.
PACB' s Net-margin (%) Range Over the Past 10 Years
Min: -64965.19  Med: -343.3 Max: -34.16
Current: -56.04
-64965.19
-34.16
ROE (%) -69.14
PACB's ROE (%) is ranked lower than
70% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. PACB: -69.14 )
Ranked among companies with meaningful ROE (%) only.
PACB' s ROE (%) Range Over the Past 10 Years
Min: -272.85  Med: -75.81 Max: -46.42
Current: -69.14
-272.85
-46.42
ROA (%) -41.54
PACB's ROA (%) is ranked lower than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. PACB: -41.54 )
Ranked among companies with meaningful ROA (%) only.
PACB' s ROA (%) Range Over the Past 10 Years
Min: -81.89  Med: -52.54 Max: -24.81
Current: -41.54
-81.89
-24.81
ROC (Joel Greenblatt) (%) -482.87
PACB's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. PACB: -482.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PACB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1441.77  Med: -697.71 Max: -379.83
Current: -482.87
-1441.77
-379.83
Revenue Growth (3Y)(%) 38.10
PACB's Revenue Growth (3Y)(%) is ranked higher than
85% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PACB: 38.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PACB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 20.6 Max: 38.8
Current: 38.1
0
38.8
EBITDA Growth (3Y)(%) -40.40
PACB's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. PACB: -40.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PACB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -56.3 Max: -24.1
Current: -40.4
EPS Growth (3Y)(%) -37.10
PACB's EPS Growth (3Y)(%) is ranked lower than
83% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. PACB: -37.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PACB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -55.3 Max: -22.6
Current: -37.1
GuruFocus has detected 3 Warning Signs with Pacific Biosciences of California Inc $PACB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PACB Guru Trades in Q4 2015

Jim Simons 1,586,400 sh (New)
Lee Ainslie 7,561,268 sh (+1.41%)
Murray Stahl 12,000 sh (unchged)
Ronald Muhlenkamp Sold Out
Steven Cohen 6,200 sh (-63.74%)
» More
Q1 2016

PACB Guru Trades in Q1 2016

Paul Tudor Jones 18,800 sh (New)
Steven Cohen 706,500 sh (+11295.16%)
Lee Ainslie 7,561,268 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Jim Simons 1,188,700 sh (-25.07%)
» More
Q2 2016

PACB Guru Trades in Q2 2016

Paul Tudor Jones 32,921 sh (+75.11%)
Lee Ainslie 7,820,808 sh (+3.43%)
Murray Stahl 12,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons 404,064 sh (-66.01%)
» More
Q3 2016

PACB Guru Trades in Q3 2016

Lee Ainslie 9,095,663 sh (+16.30%)
Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 374,900 sh (-7.22%)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 334516    SIC: 3826
Compare:OTCPK:ZLDPF, NAS:AVDL, NAS:CTMX, NAS:CYTK, NAS:MCRB, NAS:BCRX, NAS:ATRA, NAS:CERS, NAS:OMER, NAS:NTLA, NAS:OTIC, NAS:MACK, NAS:IMMU, NAS:PDLI, NAS:MESO, NAS:MRUS, NAS:INO, NAS:MYOK, NAS:XBIT, NAS:FOMX » details
Traded in other countries:P09.Germany,
Pacific Biosciences of California Inc is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

Pacific Biosciences of California Inc was incorporated in the State of Delaware in 2000. The Company develops, manufactures and markets an integrated platform for high resolution genetic analysis. It has developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, it created a technology platform using its proprietary single molecule, real-time, or SMRT, technology. Its SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events. The ability to observe single molecule events in real time provides the scientific community with a tool for investigating basic biochemical processes such as DNA synthesis. Its SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. It has commercialized the PacBioRS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, its products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The Company's products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS. Its competitors include Illumina Inc. and Thermo Fisher Scientific Inc. The names "Pacific Biosciences," "PacBio," "SMRT," "SMRTbell" and its logo are the trademarks of the Company. It is subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters.

Guru Investment Theses on Pacific Biosciences of California Inc

Meridian Funds Comments on Pacific Biosciences of California Inc. - Mar 08, 2016

Pacific Biosciences of California Inc. (NASDAQ:PACB) is a leader in the field of next-generation gene sequencing technology. In October, the company unveiled the Sequel™ System, a gene-sequencing platform that is smaller and less expensive than the Pacific Bioscience’s former gene sequencer. This groundbreaking technology enables longer and more accurate reads of genomes, and is the result of collaboration with Roche, a health care company with interests in human in vitro diagnostics. Late in the period, Pacific Biosciences received a $20 million milestone payment from Roche for completing the project. We believe this new platform will enable the company to penetrate a larger portion of the broader sequencing market.







From the Meridian Small Cap Growth Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Pacific Biosciences of California Inc

Meridian Funds Comments on Pacific Biosciences of California Inc. Guru stock highlight
Pacific Biosciences of California Inc. (NASDAQ:PACB) is a leader in the field of next-generation gene sequencing technology. In October, the company unveiled the Sequel™ System, a gene-sequencing platform that is smaller and less expensive than the Pacific Bioscience’s former gene sequencer. This groundbreaking technology enables longer and more accurate reads of genomes, and is the result of collaboration with Roche, a health care company with interests in human in vitro diagnostics. Late in the period, Pacific Biosciences received a $20 million milestone payment from Roche for completing the project. We believe this new platform will enable the company to penetrate a larger portion of the broader sequencing market. Read more...

Ratios

vs
industry
vs
history
P/B 4.26
PACB's P/B is ranked lower than
58% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. PACB: 4.26 )
Ranked among companies with meaningful P/B only.
PACB' s P/B Range Over the Past 10 Years
Min: 0.52  Med: 4.15 Max: 19.08
Current: 4.26
0.52
19.08
P/S 3.73
PACB's P/S is ranked higher than
76% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. PACB: 3.73 )
Ranked among companies with meaningful P/S only.
PACB' s P/S Range Over the Past 10 Years
Min: 1.99  Med: 7.28 Max: 27.11
Current: 3.73
1.99
27.11
Current Ratio 3.81
PACB's Current Ratio is ranked lower than
53% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. PACB: 3.81 )
Ranked among companies with meaningful Current Ratio only.
PACB' s Current Ratio Range Over the Past 10 Years
Min: 2.22  Med: 6.31 Max: 14.06
Current: 3.81
2.22
14.06
Quick Ratio 3.30
PACB's Quick Ratio is ranked lower than
56% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. PACB: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
PACB' s Quick Ratio Range Over the Past 10 Years
Min: 1.92  Med: 5.87 Max: 13.74
Current: 3.3
1.92
13.74
Days Inventory 113.64
PACB's Days Inventory is ranked higher than
55% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. PACB: 113.64 )
Ranked among companies with meaningful Days Inventory only.
PACB' s Days Inventory Range Over the Past 10 Years
Min: 103.43  Med: 164.72 Max: 196.1
Current: 113.64
103.43
196.1
Days Sales Outstanding 42.39
PACB's Days Sales Outstanding is ranked higher than
67% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. PACB: 42.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
PACB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.52  Med: 31.89 Max: 74.35
Current: 42.39
20.52
74.35
Days Payable 72.19
PACB's Days Payable is ranked higher than
59% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. PACB: 72.19 )
Ranked among companies with meaningful Days Payable only.
PACB' s Days Payable Range Over the Past 10 Years
Min: 28.8  Med: 44.07 Max: 83.1
Current: 72.19
28.8
83.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.50
PACB's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. PACB: -12.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PACB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -380.3  Med: -10.4 Max: 0
Current: -12.5
-380.3
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.89
PACB's Price/Net Cash is ranked lower than
70% of the 516 Companies
in the Global Biotechnology industry.

( Industry Median: 5.83 vs. PACB: 11.89 )
Ranked among companies with meaningful Price/Net Cash only.
PACB' s Price/Net Cash Range Over the Past 10 Years
Min: 1.02  Med: 6.69 Max: 366
Current: 11.89
1.02
366
Price/Net Current Asset Value 5.95
PACB's Price/Net Current Asset Value is ranked lower than
52% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 5.63 vs. PACB: 5.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PACB' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.89  Med: 5.36 Max: 19.89
Current: 5.95
0.89
19.89
Price/Tangible Book 4.22
PACB's Price/Tangible Book is ranked higher than
50% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. PACB: 4.22 )
Ranked among companies with meaningful Price/Tangible Book only.
PACB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.8  Med: 4.68 Max: 14.29
Current: 4.22
0.8
14.29
Price/Median PS Value 0.51
PACB's Price/Median PS Value is ranked higher than
79% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. PACB: 0.51 )
Ranked among companies with meaningful Price/Median PS Value only.
PACB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 0.98 Max: 3.6
Current: 0.51
0.4
3.6
Earnings Yield (Greenblatt) (%) -22.14
PACB's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. PACB: -22.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PACB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -23.06  Med: 366.9 Max: 26741.7
Current: -22.14
-23.06
26741.7

More Statistics

Revenue (TTM) (Mil) $101.3
EPS (TTM) $ -0.64
Beta2.79
Short Percentage of Float22.27%
52-Week Range $3.76 - 13.98
Shares Outstanding (Mil)92.65

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.85
EPS w/o NRI ($) -0.85
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Pacific Biosciences of California Inc. Mar 08 2016 
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems Jan 17 2017
Novogene Agrees to Buy Ten PacBio Sequel Systems for DNA Sequencing Services Jan 16 2017
More Than 115 Presentations and Posters Feature PacBio SMRT Sequencing to Decipher Complex Plant and... Jan 12 2017
UPDATE -- Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and... Jan 09 2017
Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software... Jan 09 2017
GrandOmics Endorses Pacific Biosciences of California (PACB) Sequel System With New Purchase Jan 05 2017
GrandOmics Biosciences Expands Investment in PacBio’s Sequel Systems for Precision Medicine... Jan 04 2017
GrandOmics Biosciences Expands Investment in PacBio’s Sequel Systems for Precision Medicine... Jan 04 2017
ETFs with exposure to Pacific Biosciences of California, Inc. : December 19, 2016 Dec 19 2016
Pacific Biosciences Terminates SMRT Agreement with Roche Dec 16 2016
Valeant, HiMax Lead Thursday’s 52-Week Low Club Dec 15 2016
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Termination of a Material Definitive... Dec 15 2016
PacBio Announces Termination of Agreement with Roche Diagnostics Dec 15 2016
Is Pacific Biosciences of California (PACB) a Good Stock to Buy? Dec 09 2016
ETFs with exposure to Pacific Biosciences of California, Inc. : December 8, 2016 Dec 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)